Arrow and Apotex merger unopposed by The Australian Competition and Consumer Commission
21 September 2018 -

The integration of generic pharmaceutical companies Arrow and Apotex has not been opposed by The Australian Competition and Consumer Commission, it was reported yesterday.

This decision has been taken after finding that the transaction would not reduce the competition in any market.

In May 2018, Apotex Australia announced a merger of its Australian and New Zealand generic pharmaceutical and over-the-counter operations with Arrow Pharmaceuticals. The combined firm is likely to distribute around half the market for generic prescription pharmaceuticals to pharmacies in Australia.